Chronic myeloid leukemia

Indexed in Crossref

23 abstracts matching chronic myeloid leukemia from the meeting's journal supplement, fetched live from Crossref 2026-11-12 08:22 UTC. This is a keyword search, not the complete abstract book.

• E18601
  Molecular remission after tyrosine kinase inhibitor cessation in chronic myeloid leukemia (CML): A systematic review and meta-analysis.

  Songphol Tungjitviboonkun, Brian Schult, Christopher Seaman
• 6510
  Updated efficacy and safety of olverembatinib (HQP1351) as second-line therapy in patients with chronic-phase chronic myeloid leukemia (CP-CML).

  Weiming Li, Yanli Zhang, Huanling Zhu, Yunfan Yang et al.
• E23076
  Asciminib in newly diagnosed Philadelphia chromosom–positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP): A retrospective chart review study in the US.

  Ehab L. Atallah, Islam Sadek, Andrea Damon, Daisy Yang et al.
• 6584
  Upfront low-dose diet-modified nilotinib versus standard imatinib in Indian patients with newly diagnosed chronic-phase chronic myeloid leukemia: The NILLOW phase II randomised trial.

  Deepak Garg
• 6583
  ASC4FIRST wk 144 analysis: Efficacy and safety and tolerability with asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed (ND) chronic myeloid leukemia in chronic phase (CML-CP).

  Jorge E. Cortes, Andreas Hochhaus, Naoto Takahashi, Ghayas C. Issa et al.
• 6513
  Olverembatinib (HQP1351) combined with blinatumomab in patients with lymphoid blast phase chronic myeloid leukemia (CML-LBP) or Philadelphia chromosome–positive B-cell precursor acute lymphoblastic leukemia (Ph + BCP-ALL).

  Elias Jabbour, Maria R. Baer, Anthony Hunter, Dennis Dong Hwan Kim et al.
• 6581
  Beyond haematological control: Long-term renal outcomes of imatinib therapy in chronic myeloid leukaemia.

  Rachana Chennamaneni, Sadashivudu Gundeti, Meher Lakshmi Konatam, Stalin Chowdary Bala
• E18599
  Survival impact of post-transplant tyrosine kinase inhibitor therapy in chronic myeloid leukemia.

  Muhammad Mujtaba Bhinder, Haris Sohail, Jennifer Collins, Salah Ud Din Safi et al.
• TPS6608
  A phase 3 study of olverembatinib (HQP1351) in patients with chronic-phase chronic myeloid leukemia: POLARIS-2 trial in progress.

  Elias Jabbour, Hagop M. Kantarjian, Anna Turkina, Elza Lomaia et al.
• 6585
  Clinical fidelity of large language models in chronic myeloid leukemia: A multimodel comparative study.

  Meenal Gehlawat, Ayush Sharma, Hiren Koshiya, Maria Alejandra Molina Rodriguez et al.
• 6591
  Safety and efficacy of asciminib in veterans with chronic myeloid leukemia.

  Omar Shukri Yaghi, Puneet Gill, Jacqueline Rose, Shanshan Liu et al.
• TPS6606
  ASC4Kids-2: Asciminib in pediatric chronic myeloid leukemia with or without T315I.

  Nobuko Hijiya, Andrew E. Place, Cornelia Garnitz, Ana Paula Cardoso et al.
• E18598
  Molecular characterization of ABL kinase domain mutations associated with imatinib resistance in chronic myeloid leukemia patients, including a novel pathogenic D276V variant.

  Soufiyan Rehioui, Brahim El Hejjioui, Abdelhamid Bouramtane, Hajar EL Azami EL Idrissi
• E18595
  Real-world comparative outcomes of first-generation versus second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia: A global propensity-matched analysis.

  Uchenna Maureen Amaechi, Mrinalini Deverapal, Oladayo Oyebanji, Olanipekun Lanny Ntukidem et al.
• E18596
  Prognostic impact of ASXL1 somatic mutation on patients with chronic myeloid leukemia: A systemic review and meta-analysis.

  Rita Ahmad, Motaz Almahmood, Rasha Kaddoura, Marrita Rabadi et al.
• 6598
  Outcomes and responsiveness of standard tyrosine kinase inhibitor dose versus dose de-escalation in chronic myeloid leukemia: A single-center retrospective study.

  Mark Pusung, Christopher Eide, Andy Kaempf, Nicola Long et al.
• 6589
  Phase II trial of asciminib for newly diagnosed chronic myeloid leukemia.

  Maria Hachem, Fadi Haddad, Elias Jabbour, Ghayas C. Issa et al.
• E18501
  Comparative analysis of mortality trends in acute versus chronic myeloid leukemia in the U.S. population with time series projection: A CDC WONDER–based study (1999–2023).

  Muhammad Saim, Anid Hassan, Sheraz Qasim, Amna Ghaffar et al.
• E18604
  Cardiovascular toxicity of second-generation TKIs versus imatinib in first-line chronic myeloid leukemia: An updated systematic review and meta-analysis.

  María Fernanda Gutiérrez Aguilera, Victor Andres Castillo, Mauricio Alejandro Saldana, Victor Anghelo Mañuico Antay et al.
• 6579
  Real-world outcomes of 7+3 versus azacitidine/venetoclax in CML transformed to AML.

  Muhammad Mujtaba Bhinder, Haris Sohail, Jennifer Collins, Salah Ud Din Safi et al.
• 6582
  Durable treatment-free remission in CML beyond clinical trials: Lessons from a large single-center real-world experience.

  Sadashivudu Gundeti, Rachana Chennamaneni, Meher Lakshmi Konatam, Stalin Chowdary Bala et al.
• E18594
  Beyond imatinib: Real-world mortality patterns across modern second-line TKIs in CML.

  Sonia Babu, Drew Clippert, Darsh Patel, Berkha Rani et al.
• E15117
  From biological complexity to clinical precision: A first-in-class single-patient–level AI strategy for precision drug repurposing in relapsed, refractory, or metastatic cancers using COSMIC mutational signatures with blast-crisis CML as a model.

  Zafar Iqbal, Abdulkareem AlGarni, Lubna Alnuaim, Azfar Athar Ishaqui et al.